Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies

被引:21
|
作者
O'Rourke, Sara M. [1 ]
Schweighardt, Becky [2 ]
Phung, Pham [2 ]
Mesa, Kathryn A. [1 ]
Vollrath, Aaron L. [1 ]
Tatsuno, Gwen P. [1 ]
To, Briana [1 ]
Sinangil, Faruk [3 ]
Limoli, Kay [2 ]
Wrin, Terri [2 ]
Berman, Phillip W. [1 ]
机构
[1] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA
[2] Monogram Biosci, San Francisco, CA USA
[3] Global Solut Infect Dis, Santa Cruz, CA USA
基金
美国国家卫生研究院;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 ENVELOPE GLYCOPROTEIN; HUMAN MONOCLONAL-ANTIBODIES; N-LINKED GLYCAN; SUBTYPE-B; CD4-BOUND CONFORMATION; CORECEPTOR TROPISM; VARIABLE LOOPS; V1/V2; DOMAIN; GP120;
D O I
10.1128/JVI.01352-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The swarm of quasispecies that evolves in each HIV-1-infected individual represents a source of closely related Env protein variants that can be used to explore various aspects of HIV-1 biology. In this study, we made use of these variants to identify mutations that confer sensitivity and resistance to the broadly neutralizing antibodies found in the sera of selected HIV-1-infected individuals. For these studies, libraries of Env proteins were cloned from infected subjects and screened for infectivity and neutralization sensitivity. The nucleotide sequences of the Env proteins were then compared for pairs of neutralization-sensitive and -resistant viruses. In vitro mutagenesis was used to identify the specific amino acids responsible for the neutralization phenotype. All of the mutations altering neutralization sensitivity/resistance appeared to induce conformational changes that simultaneously enhanced the exposure of two or more epitopes located in different regions of gp160. These mutations appeared to occur at unique positions required to maintain the quaternary structure of the gp160 trimer, as well as conformational masking of epitopes targeted by neutralizing antibodies. Our results show that sequences in gp41, the CD4 binding site, and the V2 domain all have the ability to act as global regulators of neutralization sensitivity. Our results also suggest that neutralization assays designed to support the development of vaccines and therapeutics targeting the HIV-1 Env protein should consider virus variation within individuals as well as virus variation between individuals.
引用
收藏
页码:12105 / 12114
页数:10
相关论文
共 50 条
  • [1] Phenotypic analysis of HIV-1 resistance to CD4 binding site broadly-neutralizing antibodies
    Shrader, Hannah
    Hait, Sabrina Helmold
    Lovelace, Sarah
    Kilner, Meaghan
    Shen, Chen-Hsiang
    Coates, Emily
    Gaudinski, Martin
    Rothwell, Ro Shauna
    Donaghy, Eileen
    Roa, Jhoanna
    Fichtenbaum, Carl
    Santana, Jorge
    Presti, Rachel M.
    Bhatnager, Anjali
    Lynch, Rebecca
    Tebas, Pablo
    Ledgerwood, Julie
    Mascola, John
    Koup, Richard
    Pegu, Amarendra
    [J]. JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [2] HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
    Verkoczy, Laurent
    Kelsoe, Garnett
    Haynes, Barton F.
    [J]. PLOS PATHOGENS, 2014, 10 (05)
  • [3] Retracted: Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
    D Han
    H Habte
    Y Qin
    K Takamoto
    C LaBranche
    D Montefiori
    MW Cho
    [J]. Retrovirology, 9
  • [4] A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies
    Frey, Gary
    Peng, Hanqin
    Rits-Volloch, Sophia
    Morelli, Marco
    Cheng, Yifan
    Chen, Bing
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (10) : 3739 - 3744
  • [5] Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner
    Musich, Thomas
    Li, Liuzhe
    Liu, Lily
    Zolla-Pazner, Susan
    Robert-Guroff, Marjorie
    Gorny, Miroslaw K.
    [J]. JOURNAL OF VIROLOGY, 2017, 91 (08)
  • [6] Retraction Note: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
    D Han
    H Habte
    Y Qin
    K Takamoto
    C LaBranche
    D Montefiori
    MW Cho
    [J]. Retrovirology, 11
  • [7] A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site
    Li, Liuzhe
    Wang, Xiao-Hong
    Williams, Constance
    Volsky, Barbara
    Steczko, Olivia
    Seaman, Michael S.
    Luthra, Kalpana
    Nyambi, Phillipe
    Nadas, Arthur
    Giudicelli, Veronique
    Lefranc, Marie-Paule
    Zolla-Pazner, Susan
    Gorny, Miroslaw K.
    [J]. MOLECULAR IMMUNOLOGY, 2015, 66 (02) : 364 - 374
  • [8] Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies
    Zhou, Panpan
    Wang, Han
    Fang, Mengqi
    Li, Yangyang
    Wang, Hua
    Shi, Shasha
    Li, Zihao
    Wu, Jiapeng
    Han, Xiaoxu
    Shi, Xuanling
    Shang, Hong
    Zhou, Tongqing
    Zhang, Linqi
    [J]. PLOS PATHOGENS, 2019, 15 (06)
  • [9] CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants
    Dreja, Hanna
    Pade, Corinna
    Chen, Lei
    McKnight, Aine
    [J]. JOURNAL OF GENERAL VIROLOGY, 2015, 96 : 1899 - 1905
  • [10] Multiple Pathways of HIV-1 Autologous Neutralizing Antibodies Cooperate to Drive CD4 Binding Site Broadly Neutralizing Antibody Responses
    Gao, F.
    Bonsignori, M.
    Liao, H.
    Kumar, A.
    Xia, S.
    Cai, F.
    Lu, X.
    Kozink, D. M.
    Kwong, P.
    Zhou, T.
    Lynch, R.
    Alam, S. M.
    Ferrari, G.
    Kelsoe, G.
    Sandrasegaram, G.
    Shaw, G. M.
    Hahn, B. H.
    Montefiori, D. C.
    Kamanga, G.
    Cohen, M.
    Braber, P.
    Korber, B. T.
    Mascola, J. R.
    Kepler, T. B.
    Haynes, B. F.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A186 - A186